Protagenic Therapeutics (PTIX) vs. TechTarget (TTGT) Financial Survey

Share on StockTwits

Protagenic Therapeutics (OTCMKTS:PTIX) and TechTarget (NASDAQ:TTGT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares Protagenic Therapeutics and TechTarget’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protagenic Therapeutics N/A N/A -$2.25 million N/A N/A
TechTarget $121.33 million 3.53 $12.95 million $0.45 33.98

TechTarget has higher revenue and earnings than Protagenic Therapeutics.

Institutional & Insider Ownership

73.1% of TechTarget shares are owned by institutional investors. 51.1% of Protagenic Therapeutics shares are owned by insiders. Comparatively, 27.1% of TechTarget shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Protagenic Therapeutics has a beta of -9.02, suggesting that its stock price is 1,002% less volatile than the S&P 500. Comparatively, TechTarget has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Profitability

This table compares Protagenic Therapeutics and TechTarget’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protagenic Therapeutics N/A -323.42% -184.81%
TechTarget 10.68% 10.06% 7.50%

Analyst Recommendations

This is a summary of current ratings for Protagenic Therapeutics and TechTarget, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagenic Therapeutics 0 0 0 0 N/A
TechTarget 0 1 3 0 2.75

TechTarget has a consensus target price of $27.25, suggesting a potential upside of 78.22%. Given TechTarget’s higher probable upside, analysts clearly believe TechTarget is more favorable than Protagenic Therapeutics.

Summary

TechTarget beats Protagenic Therapeutics on 9 of the 10 factors compared between the two stocks.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.

TechTarget Company Profile

TechTarget, Inc. provides specialized online content for buyers of enterprise information technology (IT) products and services in the United States, the United Kingdom, and internationally. It also provides purchase-intent marketing and sales services for enterprise technology vendors; and customized marketing programs that integrate demand generation and brand marketing, as well as advertising techniques, which enable IT vendors to identify, reach, and influence corporate IT decision makers who are researching specific IT purchases. The company offers online services, including IT Deal Alert, core online, demand solutions, brand solutions, and custom content creation. It also operates an integrated content platform that consists of a network of approximately 140 Websites that focus on a specific IT sector, such as storage, security, networking, or business applications. In addition, the company enables registered members to conduct their pre-purchase research by accessing vendor supplied content through a network of Websites. TechTarget, Inc. was founded in 1999 and is headquartered in Newton, Massachusetts.

Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

FineMark National Bank & Trust Sells 537 Shares of BP plc
FineMark National Bank & Trust Sells 537 Shares of BP plc
Invesco Global Water ETF  Shares Bought by Mcmillion Capital Management Inc.
Invesco Global Water ETF Shares Bought by Mcmillion Capital Management Inc.
Vanguard FTSE Pacific ETF  Shares Bought by Mcmillion Capital Management Inc.
Vanguard FTSE Pacific ETF Shares Bought by Mcmillion Capital Management Inc.
FineMark National Bank & Trust Has $6.95 Million Stake in Dollar General Corp.
FineMark National Bank & Trust Has $6.95 Million Stake in Dollar General Corp.
Stelac Advisory Services LLC Takes $197,000 Position in First Trust Preferred Securities and Income ETF
Stelac Advisory Services LLC Takes $197,000 Position in First Trust Preferred Securities and Income ETF
Foamix Pharmaceuticals Ltd  Given Consensus Recommendation of “Hold” by Brokerages
Foamix Pharmaceuticals Ltd Given Consensus Recommendation of “Hold” by Brokerages


Leave a Reply

© 2006-2019 Ticker Report